youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
CYTK:NASDAQ
Cytokinetics, Inc.
$62.03
arrow_downward
-1.52%(-0.96) 1D
$62.03
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CYTK...
Open
$63.40
High
$64.00
Low
$61.96
Mkt. cap
8.62B
Avg. vol.
1.85M
Volume
0.00
52-wk high
$88.31
52-wk low
$58.05
EPS
-$7.22
Beta
0.41
Shares outstanding
139.02M
No. of employees
673
Open
$63.40
High
$64.00
Low
$61.96
Mkt. cap
8.62B
Avg. vol.
1.85M
Volume
0.00
52-wk high
$88.31
52-wk low
$58.05
EPS
-$7.22
Beta
0.41
Shares outstanding
139.02M
No. of employees
673
News stories
From web sources and news partners
Investing.com
·
5 hours ago
Cytokinetics CEO Robert Blum sells $471,075 in CYTK stock
Profile
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. Wikipedia
About Cytokinetics, Inc.
CEORobert I. Blum | Robert I. Blum
Employees673
Founded1997
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitecytokinetics.com
Analyst ratings
Based on 15 analysts giving stock ratings to CYTK in the past 3 months
Strong buy
Buy
14
Hold
1
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for CYTK in the last 3 months.
Highest
Current $62.03
$140.00 (+125.70%)
Average
$108.23 (+74.48%)
Lowest
$81.00 (+30.58%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Joseph Pantginis H.C. Wainwright | Buy | Reiterated | $140.00 | +125.7% | 10/19/2026 |
Jason Zemansky Bank of America Securities | Hold | Reiterated | $81.00 | +30.6% | 10/19/2026 |
Unknown Analyst William Blair | Buy | Initiated | - | - | 10/15/2026 |
Leonid Timashev RBC Capital | Buy | Maintained | $113.00 | +82.2% | 10/14/2026 |
Tessa Romero J.P. Morgan | Buy | Maintained | - | - | 10/14/2026 |
Ashwani Verma UBS | Buy | Maintained | $104.00 | +67.7% | 10/15/2026 |
Serge Belanger Needham | Buy | Maintained | $112.00 | +80.6% | 10/05/2026 |
Yanan Zhu Wells Fargo | Buy | Maintained | $105.00 | +69.3% | 10/02/2026 |
Srikripa Devarakonda Truist Financial | Buy | Reiterated | $112.00 | +80.6% | 09/01/2026 |
Cory Kasimov Evercore ISI | Buy | Maintained | $100.00 | +61.2% | 08/31/2026 |
Paul Choi Goldman Sachs | Buy | Reiterated | $105.00 | +69.3% | 08/28/2026 |
Emily Field Barclays | Buy | Reiterated | $110.00 | +77.3% | 08/26/2026 |
Yasmeen Rahimi Piper Sandler | Buy | Maintained | $107.00 | +72.5% | 08/07/2026 |
James Condulis Stifel Nicolaus | Buy | Reiterated | $108.00 | +74.1% | 08/07/2026 |
Jason Butler Citizens JMP | Buy | Maintained | $110.00 | +77.3% | 08/07/2026 |
Mayank Mamtani B. Riley Securities | Buy | Reiterated | $146.00 | +135.4% | 07/31/2026 |
Maxwell Skor Morgan Stanley | Buy | Reiterated | $103.00 | +66% | 07/23/2026 |
Eric Joseph Citi | Buy | Maintained | $99.00 | +59.6% | 07/16/2026 |
Salim Syed Mizuho Securities | Buy | Maintained | $118.00 | +90.2% | 06/23/2026 |
Unknown Analyst Citi | Buy | Initiated | $99.00 | +59.6% | 05/19/2026 |
Unknown Analyst Raymond James | Hold | Maintained | - | - | 05/06/2026 |
Carter Gould Cantor Fitzgerald | Buy | Maintained | - | - | 02/25/2026 |
Next call in 39:41:52
Wed, Nov 4, 4:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$1.41
Revenue / Est. (USD)
- / 42.34M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.94M | 17.76M | 19.36M | 28.62M |
Cost of goods sold | 99.23M | 104.40M | 98.08M | 103.40M |
Cost of revenue | 99.23M | 104.40M | 98.08M | 103.40M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 69.46M | 91.72M | 104.90M | 104.40M |
Operating expense | 69.46M | 91.72M | 104.90M | 104.40M |
Total operating expenses | 168.69M | 196.12M | 202.97M | 207.80M |
Operating income | -166.76M | -178.37M | -183.62M | -179.17M |
Other non operating income | -2.10M | 14.20M | -100.00K | 1.30M |
EBT including unusual items | -306.18M | -183.03M | -206.03M | -198.76M |
EBT excluding unusual items | -184.93M | -183.03M | -206.03M | -198.76M |
Income tax expense | - | - | - | - |
Effective tax rate | - | - | - | - |
Other operating expenses | - | - | - | - |
Net income | -306.18M | -183.03M | -206.03M | -198.76M |
Net profit margin | -15,814.98% | -1,030.87% | -1,064.48% | -694.39% |
Earnings per share | -1.54 | -1.50 | -1.67 | -1.50 |
Interest and investment income | 10.25M | 11.47M | 11.02M | 13.94M |
Interest expense | -26.32M | -30.34M | -33.34M | -34.83M |
Net interest expenses | -16.07M | -18.86M | -22.31M | -20.89M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -164.08M | -175.50M | -180.24M | -175.54M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events